ALK and non-small cell lung carcinoma: In an initial phase I dose-escalation portion of the AF-001JP study, treatment of 24 crizotinib-naïve patients with recurrent/relapsed ALK+ NSCLC with alectinib at doses ranging from 20–300 mg twice daily was found to be safe and well tolerated [81].